Islet autoantibodies and residual beta cell function in type 1 diabetes children followed for 3-6 years
Sorensen, J. S. ; Vaziri Sani, Fariba LU ; Maziarz, M. ; Kristensen, K. ; Ellerman, A. ; Breslow, N. ; Lernmark, Åke LU
; Pociot, F.
; Brorsson, C.
and Birkebaek, N. H.
(2012)
In Diabetes Research and Clinical Practice
96(2).
p.204-210
- Abstract
- Aims: To test if islet autoantibodies at diagnosis of type 1 diabetes (T1DM) and after 3-6 years with T1D predict residual beta-cell function (RBF) after 3-6 years with T1D. Methods: T1D children (n = 260, median age at diagnosis 9.4, range 0.9-14.7 years) were tested for GAD65, IA-2, ZnT8R, ZnT8W and ZnT8Q autoantibodies (A) at diagnosis, and 3-6 years after diagnosis when also fasting and stimulated RBF were determined. Results: For every 1-year increase in age at diagnosis of TID, the odds of detectable C-peptide increased 1.21 (1.09, 1.34) times for fasting C-peptide and 1.28 (1.15, 1.42) times for stimulated C-peptide. Based on a linear model for subjects with no change in IA-2A levels, the odds of detectable C-peptide were 35% higher... (More)
- Aims: To test if islet autoantibodies at diagnosis of type 1 diabetes (T1DM) and after 3-6 years with T1D predict residual beta-cell function (RBF) after 3-6 years with T1D. Methods: T1D children (n = 260, median age at diagnosis 9.4, range 0.9-14.7 years) were tested for GAD65, IA-2, ZnT8R, ZnT8W and ZnT8Q autoantibodies (A) at diagnosis, and 3-6 years after diagnosis when also fasting and stimulated RBF were determined. Results: For every 1-year increase in age at diagnosis of TID, the odds of detectable C-peptide increased 1.21 (1.09, 1.34) times for fasting C-peptide and 1.28 (1.15, 1.42) times for stimulated C-peptide. Based on a linear model for subjects with no change in IA-2A levels, the odds of detectable C-peptide were 35% higher than for subjects whose IA-2A levels decreased by half (OR = 1.35 (1.09, 1.67), p = 0.006); similarly for ZnT8WA (OR = 1.39 (1.09, 1.77), p = 0.008) and ZnT8QA (OR = 1.55 (1.06, 2.26) p = 0.024). Such relationship was not detected for GADA or ZnT8RA. All OR adjusted for confounders. Conclusions: Age at diagnosis with T1D was the major predictor of detectable C-peptide 3-6 years post-diagnosis. Decreases in IA-2A, and possibly ZnT8A, levels between diagnosis and post-diagnosis were associated with a reduction in RBF post-diagnosis. (C) 2012 Elsevier Ireland Ltd. All rights reserved. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2826588
- author
- Sorensen, J. S.
; Vaziri Sani, Fariba
LU
; Maziarz, M.
; Kristensen, K.
; Ellerman, A.
; Breslow, N.
; Lernmark, Åke
LU
; Pociot, F.
; Brorsson, C.
and Birkebaek, N. H.
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- GAD65 autoantibodies, IA-2 autoantibodies, ZnT8 autoantibodies, Residual, beta cell function, Age at diagnosis
- in
- Diabetes Research and Clinical Practice
- volume
- 96
- issue
- 2
- pages
- 204 - 210
- publisher
- Elsevier
- external identifiers
-
- wos:000303668000026
- scopus:84860533291
- pmid:22251574
- ISSN
- 1872-8227
- DOI
- 10.1016/j.diabres.2011.12.013
- language
- English
- LU publication?
- yes
- id
- 07937b81-1274-4d4b-8fab-f8c4a80bf2a2 (old id 2826588)
- date added to LUP
- 2016-04-01 10:21:27
- date last changed
- 2022-03-22 13:04:27
@article{07937b81-1274-4d4b-8fab-f8c4a80bf2a2,
abstract = {{Aims: To test if islet autoantibodies at diagnosis of type 1 diabetes (T1DM) and after 3-6 years with T1D predict residual beta-cell function (RBF) after 3-6 years with T1D. Methods: T1D children (n = 260, median age at diagnosis 9.4, range 0.9-14.7 years) were tested for GAD65, IA-2, ZnT8R, ZnT8W and ZnT8Q autoantibodies (A) at diagnosis, and 3-6 years after diagnosis when also fasting and stimulated RBF were determined. Results: For every 1-year increase in age at diagnosis of TID, the odds of detectable C-peptide increased 1.21 (1.09, 1.34) times for fasting C-peptide and 1.28 (1.15, 1.42) times for stimulated C-peptide. Based on a linear model for subjects with no change in IA-2A levels, the odds of detectable C-peptide were 35% higher than for subjects whose IA-2A levels decreased by half (OR = 1.35 (1.09, 1.67), p = 0.006); similarly for ZnT8WA (OR = 1.39 (1.09, 1.77), p = 0.008) and ZnT8QA (OR = 1.55 (1.06, 2.26) p = 0.024). Such relationship was not detected for GADA or ZnT8RA. All OR adjusted for confounders. Conclusions: Age at diagnosis with T1D was the major predictor of detectable C-peptide 3-6 years post-diagnosis. Decreases in IA-2A, and possibly ZnT8A, levels between diagnosis and post-diagnosis were associated with a reduction in RBF post-diagnosis. (C) 2012 Elsevier Ireland Ltd. All rights reserved.}},
author = {{Sorensen, J. S. and Vaziri Sani, Fariba and Maziarz, M. and Kristensen, K. and Ellerman, A. and Breslow, N. and Lernmark, Åke and Pociot, F. and Brorsson, C. and Birkebaek, N. H.}},
issn = {{1872-8227}},
keywords = {{GAD65 autoantibodies; IA-2 autoantibodies; ZnT8 autoantibodies; Residual; beta cell function; Age at diagnosis}},
language = {{eng}},
number = {{2}},
pages = {{204--210}},
publisher = {{Elsevier}},
series = {{Diabetes Research and Clinical Practice}},
title = {{Islet autoantibodies and residual beta cell function in type 1 diabetes children followed for 3-6 years}},
url = {{https://lup.lub.lu.se/search/files/1779189/3124961.pdf}},
doi = {{10.1016/j.diabres.2011.12.013}},
volume = {{96}},
year = {{2012}},
}